1. IQVIA. The impact of biosimilar competition in Europe. Quintiles IMS. 2018;2018:33.
2. IMS. Delivering on the potential of biosimilar medicines: the role of functioning competitive markets introduction. IMS Inst Healthc Informatics. 2016;2016:40.
3. Wolff-Holz E, Tiitso K, Vleminckx C, Weise M. Evolution of the EU biosimilar framework: past and future. BioDrugs. 2019.
https://doi.org/10.1007/s40259-019-00377-y
.
4. European Medicines Agency. Biosimilar medicines. 2019.
https://www.ema.europa.eu/en/medicines/field_ema_web_categories%253Aname_field/Human/ema_group_types/ema_medicine/field_ema_med_status/authorised-36/ema_medicine_types/field_ema_med_biosimilar/search_api_aggregation_ema_medicine_types/field_ema_med_biosim
. Accessed 9 Sep 2019.
5. Harston A. FDA’s biosimilar approvals accelerate in 2018: how the US compares to Europe on biosimilar approvals and products in the pipeline. 2019.
https://www.biosimilarsip.com/2019/02/05/fdas-biosimilar-approvals-accelerate-in-2018-how-the-u-s-compares-to-europe-on-biosimilar-approvals-and-products-in-the-pipeline/
. Accessed 13 Sep 2019.